GBA1 and Parkinson disease: The second advantage of access to a repurposed drug is indeed relevant to Ambroxol, and many patients with nGD, as well as those with GBA1-related PD or even idiopathic PD, have begun using it with satisfactory results without the need to wait for lengthy clinical trials [27].